Obrixtamig

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameObrixtamig
Drug Alias NameBI-764532OBT620
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Delta-like protein 3Anti-CD3
TargetsDelta-like protein 3T cell surface glycoprotein CD3
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, NeuroendocrineNeuroendocrine Tumors +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgSino Biopharmaceutical LtdBoehringer Ingelheim Pharma Gmbh & Co Kg +[8] 
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, NeuroendocrineNeuroendocrine Tumors +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A